These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18577955)

  • 1. [Mirapex (pramipexole) in the treatment of non-motor disturbances in Parkinson's disease].
    Nodel' MR; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(5):32-8. PubMed ID: 18577955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dopamine receptors agonists (mirapex) in the treatment of Parkinson's disease].
    Fedorova NV; Chigir' IP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):26-33. PubMed ID: 16841480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [7-year experience in usage of mirapex in patients with different forms of primary parkinsonism].
    Illarioshkin SN; Ivanova-Smolenskaia IA; Zagorovskaia TB; Karabanov AV; Poleshchuk VV; Markova ED; Karpova EA; Polevaia EV; Bagyeva GKh; Timerbaeva SL; Nurmanova ShA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(11):26-32. PubMed ID: 17180757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of the dopamine agonist mirapex (pramipexole) therapy on sleep disorders in Parkinson's disease].
    Nodel' MR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(3):42-7. PubMed ID: 20517225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fatigability in Parkinson's disease].
    Nodel' MR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(9):23-6. PubMed ID: 19770828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PSYCHOPHARMACOLOGY OF ANTIPARKINSONIAN DRUGS].
    Arushanyan EB; Naumov SS
    Eksp Klin Farmakol; 2017; 80(1):32-38. PubMed ID: 29874001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease.
    Fedorova NV; Chigir' IP
    Neurosci Behav Physiol; 2007 Jul; 37(6):539-46. PubMed ID: 17657423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
    Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease].
    Levin OS; Nesterova OS; Otcheskaia OV; Zhuravleva EIu; Artemova IIu; Khozova AA; Ismailov AM; Lisenker LN; Vdovichenko TV; Rotor LD; Ganzula PA; Ivanov AK; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):36-41. PubMed ID: 19738567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
    Xiang W; Sun YQ; Teoh HC
    Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.
    Lemke MR; Brecht HM; Koester J; Kraus PH; Reichmann H
    J Neuropsychiatry Clin Neurosci; 2005; 17(2):214-20. PubMed ID: 15939976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy Use for Non-Motor Symptoms Among de novo Parkinson's Disease Parkinson's Progression Markers Initiative Participants.
    Javidnia M; Shoulson I; Kieburtz K; Venuto CS
    J Parkinsons Dis; 2020; 10(3):1239-1243. PubMed ID: 32417797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole extended release in Parkinson's disease.
    Hametner EM; Seppi K; Poewe W
    Expert Rev Neurother; 2011 Sep; 11(9):1229-34. PubMed ID: 21864066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 17. Pramipexole extended-release: a review of its use in patients with Parkinson's disease.
    Frampton JE
    Drugs; 2014 Dec; 74(18):2175-90. PubMed ID: 25385556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
    Dooley M; Markham A
    Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
    Lemke MR; Brecht HM; Koester J; Reichmann H
    J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pramipexole dose-response relationships in Parkinson's disease.
    Wang Y; Sun SG; Zhu SQ; Liu CF; Liu YM; Di Q; Shang HF; Ren Y; Xiang W; Chen SD
    Drug Des Devel Ther; 2017; 11():83-89. PubMed ID: 28096656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.